<DOC>
	<DOCNO>NCT00114699</DOCNO>
	<brief_summary>This phase 1 , randomize , placebo-controlled , dose-escalation study CCR5mAb004 HIV-1 seropositive individual receive concurrent antiretroviral therapy . Subjects randomly assign receive single intravenous ( IV ) infusion one four dose level CCR5mAb004 match placebo . A minimum 10 subject randomize cohort ratio 4:1 ( active : placebo ) . A minimum 40 maximum 60 subject enrol . This study conduct 10 site United States . Subjects cohort follow 56 day study agent administration . The safety , tolerability , immunogenicity CCR5mAb004 evaluate base physical examination , adverse event ( AE ) reporting , clinical laboratory test . Blood collect specified time determination CCR5mAb004 serum concentration , HIV-1 RNA level , CD4+ CD8+ cell count . If CD4+ cell count less 200 study period , subject offer standard-of-care per HIV treatment guideline may include initiation appropriate anti-retroviral therapy ( AVR ) . CCR5mAb004 pharmacokinetic ( PK ) pharmacodynamics ( PD ) measure 56-day study period . Anti-CCR5mAb004 antibody titer assess prior dose Day 0 Day 28 Day 56 .</brief_summary>
	<brief_title>Safety Efficacy Antibody CCR5 Individuals With HIV Who Are Not Currently Antiretroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>HIV1 infection confirm enzyme immunoassay ( EIA ) Western blot . Age 18 64 year . HIV1 RNA &gt; 5000 copies/mL . CD4+ T cell count &gt; 250 cells/uL . Treatment na√Øve , antiretroviral treatment least 30 day prior screen 60 day prior Day 0 CCR5 tropism confirm R5 PhenoSense assay . CXCR4 tropic dual tropic virus screen . Laboratory value Grade 3 great accord Modified Division Microbiology Infectious Diseases ( DMID ) Adult Toxicity Tables . History Category C AIDSdefining illness accord 1993 Centers Disease Control Prevention ( CDC ) AIDS surveillance definition . History medical disease condition make subject ( opinion investigator ) unsuitable study . Malignancy within past 5 year ( except basal carcinoma skin situ cancer cervix ) . Females pregnant breastfeeding , plan become pregnant study . Subjects whose dosage number prescription medication change within 30 day prior screen Positive hepatitis B surface antigen ( HBsAg ) antibody hepatitis C virus ( HCV ) . Positive alcohol drug screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>